CoChat

Adoptive immunotherapy combined with intratumoral TLR agonist delivery eradicates established melanoma in mice

Open access
Amos, Sally M., Pegram, Hollie J., Westwood, Jennifer A., John, Liza B., Devaud, Christel, Clarke, Chris J., Restifo, Nicholas P., Smyth, Mark J., Darcy, Phillip K., Kershaw, Michael H. · 2011 · Cancer Immunology, Immunotherapy
Cited by 88

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Toll-like receptor (TLR) agonists can trigger broad inflammatory responses that elicit rapid innate immunity and promote the activities of lymphocytes, which can potentially enhance adoptive immunotherapy in the tumor-bearing setting. In the present study, we found that Polyinosinic:Polycytidylic Acid [Poly(I:C)] and CpG oligodeoxynucleotide 1826 [CpG], agonists for TLR 3 and 9, respectively, potently activated adoptively transferred T cells against a murine model of established melanoma. Intratumoral injection of Poly(I:C) and CpG, combined with systemic transfer of activated pmel-1 T cells, specific for gp10025–33, led to enhanced survival and eradication of 9-day established subcutaneous B16F10 melanomas in a proportion of mice. A series of survival studies in knockout mice supported a key mechanistic pathway, whereby TLR agonists acted via host cells to enhance IFN-γ production by adoptively transferred T cells. IFN-γ, in turn, enhanced the immunogenicity of the B16F10 melanoma line, leading to increased killing by adoptively transferred T cells. Thus, this combination approach counteracted tumor escape from immunotherapy via downregulation of immunogenicity. In conclusion, TLR agonists may represent advanced adjuvants within the setting of adoptive T-cell immunotherapy of cancer and hold promise as a safe means of enhancing this approach within the clinic.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00262-011-0984-8

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 88

Metadata

Authors
Amos, S. M., Pegram, H. J., Westwood, J. A., John, L. B., Devaud, C., Clarke, C. J., Restifo, N. P., Smyth, M. J., Darcy, P. K., & Kershaw, M. H.
Venue
Cancer Immunology, Immunotherapy
Published
2011-02-16
Volume
60
Issue
5
Pages
671-683
ISSN
  • 0340-7004 (ISSN-L)
  • 1432-0851
OpenAlex
W2106776403
Cited by
88
References
3
FWCI
3.56
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Adoptive immunotherapy combined with intratumoral TLR agonist delivery eradicates established melanoma in mice. https://app.cochat.ai/papers/10.1007/s00262-011-0984-8
The paper
Amos, S. M., Pegram, H. J., Westwood, J. A., John, L. B., Devaud, C., Clarke, C. J., Restifo, N. P., Smyth, M. J., Darcy, P. K., & Kershaw, M. H. (2011). Adoptive immunotherapy combined with intratumoral TLR agonist delivery eradicates established melanoma in mice. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-011-0984-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.